OptiBiotix Health PLC LPLDL® reduces high blood pressure (0633Z)
08 Enero 2020 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 0633Z
OptiBiotix Health PLC
08 January 2020
OptiBiotix Health Plc
("OptiBiotix" or the "Company")
Human study shows formulation with LP(LDL) (R) reduces high
blood pressure
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces that its fully-owned subsidiary ProBiotix
Health Ltd. ("ProBiotix"), in partnership with Nutrilinea Srl.
("Nutrilinea") has completed a successful human study for a new
food supplement formulation containing LP(LDL) (R) and has shown
the product can reduce high blood pressure (hypertension).
The study was part of an agreement (RNS: 20 May 2019) with
Nutrilinea to fund the development, manufacture, and carrying out
of human studies for a new blood pressure product in return for 12
months exclusivity from the date the data was made available from
the human study (18 December 2019) for the European market.
ProBiotix has exclusivity for the UK and all other markets outside
Europe.
The three month study of 40 patients was carried out by the
Center of Diabetes and Metabolic Diseases, Department of Internal
Medicine and Therapeutics, University of Pavia and Fondazione IRCCS
Policlinico San Matteo, Pavia, Italy and showed statistically
significant reductions in both systolic, diastolic blood pressure
levels, and cholesterol levels. The results of this study are
consistent with ProBiotix's initial study conducted at the
University of Reading which showed a statistically significant
reduction in both blood pressure and cholesterol in volunteers
taking LP(LDL) (R) (Costabile et al., 2017).
The European Cardiovascular Society reported in 2016 that the
combination of lowering LDL cholesterol and systolic blood pressure
has the potential to "dramatically reduce" a person's lifetime risk
of cardiovascular disease. Hypertension is a global healthcare
issue and is one of the strongest risk factors for almost all
cardiovascular diseases. The fact that it does not have obvious
symptoms has led doctors to call hypertension a 'silent killer'.
Studies conducted in Europe and in the United States suggest that,
under new hypertension guidelines, a large percentage of the adult
population may be considered hypertensive: some 14 million people
in the UK and over 100 million in the US.
https://www.heart.org/en/news/2018/05/01/more-than-100-million-americans-have-high-blood-pressure-aha-says
Steve Prescott, Chief Executive Officer of ProBiotix, commented:
"We are very pleased to have partnered with Nutrilinea who covered
the cost of the product development, manufacturing, and the human
study. Because hypertension effects millions of people globally and
is a serious risk factor for cardiovascular disease, we are excited
to offer a natural product that has been clinically proven to lower
hypertension. Adding this new formulation to our portfolio of
existing products that target cholesterol reduction, CholBiome(R)
and CholBiome(R) x3, allows ProBiotix to offer a best in class
cardiovascular health solutions to consumers."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking) Tel: 020 7220 0500
goetzpartners securities Limited Tel: 020 3859 7725
Ulrich Kinzel
Walbrook PR Ltd
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUBOKRROUARAR
(END) Dow Jones Newswires
January 08, 2020 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024